A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > TRENDS
TRENDS
-
Facing Unprecedented Patent Cliff for Abilify, Otsuka Holdings Sets Forth Plan to Achieve Recovery in 2018
September 24, 2014
-
Number of Females MRs Breaks 9,000 Mark with 1 in 3 in Their 20s, but Number in Management Positions Remains Low
September 19, 2014
-
With Entry of SGLT-2 Inhibitors, Competition Heating Up Again in Oral Anti-Diabetes Drug Market
September 12, 2014
-
Molecular-Targeted Treatments for Refractory Thyroid Cancer Debut, Giving Patients Hope
September 5, 2014
-
Competition Likely to Heat Up in RA Biologics Market Although Growth Continues
August 29, 2014
-
Smaller Drug Makers Actively Expanding Overseas Focus, Shedding Conventional Business Models
August 18, 2014
-
Old Giving Way to New in Osteoporosis Market as Competition among New Drugs Launched Since 2010 Increases
August 8, 2014
-
Development Activity in Pulmonary Hypertension Market Accelerates with Debut of Japan’s First CTEPH Treatment
July 23, 2014
-
Will Blopress AG Launched Prior to Patent Expiration Dominate the Market?
July 11, 2014
-
Entry of Lixiana Will Further Intensify Competition in Market for NOACs
July 4, 2014
-
With Sales of Aricept, Pariet Plummeting, Eisai to Focus on Investment in FY2014 with an Eye to Growth Track in FY2015
June 27, 2014
-
MTPC Predicts Remicade Biosimilar “Will Not Have a Major Impact”
June 20, 2014
-
Novo Nordisk Launches Hemophilia A Treatment NovoEight; Will Compete Directly with Baxter’s Advate
June 13, 2014
-
Different Stances on Biosimilars Setting Domestic Generic Houses Apart as “Post-Small Molecule” Era Approaches
June 6, 2014
-
Risk Management Could Be Key to Success of Highly Anticipated New NSCLC Treatment Giotrif
May 30, 2014
-
Cost-Reduction Becoming a Top Priority for Domestic Drug Makers Due to Sluggish Sales of Long-Listed Drugs, Impact of NHI Pricing System Reform
May 28, 2014
-
Foreign Drug Makers Seeking to Offset Risk in US, European Markets by Driving Growth in “Attractive” Japanese Market
May 23, 2014
-
With Growth in the Number of CMRs Slowing, Can JCSOA Reach Its Goal of “5,000 CMRs by the End of 2015”?
May 16, 2014
-
Shionogi’s New Midterm Business Plan Aims for Realistic Growth Targets for Domestic Sales Focusing on “Strategic Products”
April 24, 2014
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…